Bafna Pharmaceuticals Limited — Others, 26-08-2025: Shareholders meeting

Bafna Pharmaceuticals has released its Annual Report for FY2024-25, announcing its 30th Annual General Meeting for September 19. Revenue was ₹145.86 Cr, slightly down from ₹152.47 Cr, largely due to a ₹15 Cr impact from factory disruptions. PAT came in at ₹4.15 Cr (down from ₹7.35 Cr), affected by a ₹2.15 Cr intangible asset derecognition. EBITDA was ₹13.92 Cr. Strategic initiatives include Unit II capacity expansion and new product dossiers. The approved Madhavaram unit sale awaits license. Auditors noted discrepancies in bank statements for working capital, though public shareholding compliance is now resolved.